TaiMed Biologics Inc (中裕新藥) plans to apply within a month to the US Food and Drug Administration (FDA) for permission to license its Trogarzo “by intravenous push” treatment, as the company’s phase 3 clinical trial showed promising results, it said in a filing with the Taipei Exchange on Sunday.
On March 1, 2019, the HIV/AIDS drug developer began its last stage of human testing in the US to observe whether Trogarzo by intravenous push could produce the same effect as its Trogarzo “by intravenous infusion” treatment, which has already been launched.
Trogarzo by intravenous infusion needs to be diluted with saline solution and administration of the medication takes 15 minutes, while Trogarzo by intravenous push can be given to patients undiluted and takes only 30 seconds to administer, the company said.
Twenty-two people who were infected with HIV-1, but were in a stable condition and had already taken Trogarzo by intravenous infusion for at least three months, participated in the phase 3 trial, TaiMed said in the filing.
Participants initially took Trogarzo by intravenous infusion once every two weeks, but later took Trogarzo by intravenous push, also once every two weeks, the company said.
They did not report any severe adverse reactions, but some had mild or medium adverse reactions, it said.
The concentration of Trogarzo declined at similar rates in participants treated using the intravenous infusion and intravenous push methods, indicating that the different administration routes did not affect the rate of the drugs’ absorption, TaiMed said.
The different methods of administration did not lead to a change in participants’ viral loads, and no one reported viral loads of more than than 1,000 copies per milliliter twice consecutively, it said.
Meanwhile, no participants developed anti-Trogarzo antibodies, TaiMed said.
“Overall, the test results have reached our objectives. We will apply for a biologics license,” TaiMed said. “It is expected that we will obtain approval within a few months.”
TaiMed paid about US$2 million for the phase 3 clinical trail, which was carried out by a contract research organization, it said, adding that the payment excluded drug expenses and research costs.
The company said it expects to receive a milestone payment of US$3 million from its marketing and distribution partner, Theratechnologies Inc, if it gains approval from the FDA.
TaiMed has signed a 12-year contract with Theratechnologies, which would be in charge of sales of Trogarzo by intravenous push in the US, Canada, most European countries and Israel.
It has signed another contract with Meroven Ltd, which would market the medication in the Middle East and North Africa.
Merida Industry Co (美利達) has seen signs of recovery in the US and European markets this year, as customers are gradually depleting their inventories, the bicycle maker told shareholders yesterday. Given robust growth in new orders at its Taiwanese factory, coupled with its subsidiaries’ improving performance, Merida said it remains confident about the bicycle market’s prospects and expects steady growth in its core business this year. CAUTION ON CHINA However, the company must handle the Chinese market with great caution, as sales of road bikes there have declined significantly, affecting its revenue and profitability, Merida said in a statement, adding that it would
i Gasoline and diesel prices at fuel stations are this week to rise NT$0.1 per liter, as tensions in the Middle East pushed crude oil prices higher last week, CPC Corp, Taiwan (台灣中油) and Formosa Petrochemical Corp (台塑石化) said yesterday. International crude oil prices last week rose for the third consecutive week due to an escalating conflict between Israel and Iran, as the market is concerned that the situation in the Middle East might affect crude oil supply, CPC and Formosa said in separate statements. Front-month Brent crude oil futures — the international oil benchmark — rose 3.75 percent to settle at US$77.01
RISING: Strong exports, and life insurance companies’ efforts to manage currency risks indicates the NT dollar would eventually pass the 29 level, an expert said The New Taiwan dollar yesterday rallied to its strongest in three years amid inflows to the nation’s stock market and broad-based weakness in the US dollar. Exporter sales of the US currency and a repatriation of funds from local asset managers also played a role, said two traders, who asked not to be identified as they were not authorized to speak publicly. State-owned banks were seen buying the greenback yesterday, but only at a moderate scale, the traders said. The local currency gained 0.77 percent, outperforming almost all of its Asian peers, to close at NT$29.165 per US dollar in Taipei trading yesterday. The
RECORD LOW: Global firms’ increased inventories, tariff disputes not yet impacting Taiwan and new graduates not yet entering the market contributed to the decrease Taiwan’s unemployment rate last month dropped to 3.3 percent, the lowest for the month in 25 years, as strong exports and resilient domestic demand boosted hiring across various sectors, the Directorate-General of Budget, Accounting and Statistics (DGBAS) said yesterday. After seasonal adjustments, the jobless rate eased to 3.34 percent, the best performance in 24 years, suggesting a stable labor market, although a mild increase is expected with the graduation season from this month through August, the statistics agency said. “Potential shocks from tariff disputes between the US and China have yet to affect Taiwan’s job market,” Census Department Deputy Director Tan Wen-ling
RSS